Sonendo, Inc. announces the price of its initial public offering | Business

0

LAGUNA HILLS, Calif .– (BUSINESS WIRE) – October 28, 2021–

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® system, today announced the price of its initial public offering of 7,800,000 common shares at a public offering price of $ 12.00 per share, for total gross proceeds of $ 93.6 million, before the deduction of subscription discounts and commissions and estimated offering costs. All shares are offered and sold by Sonendo. Sonendo’s common stock is expected to begin trading on the New York Stock Exchange on October 29, 2021, under the symbol “SONX”. The closing of the offer is scheduled for November 2, 2021, subject to the satisfaction of the usual closing conditions. In addition, Sonendo has granted the underwriters a 30-day option to purchase up to 1,170,000 additional common shares at the initial public offering price, less subscription discounts and commissions.

BofA Securities, Goldman Sachs & Co. LLC and Piper Sandler & Co. are acting as co-managers of the books and as representatives of the proposed offering. Stifel, Nicolaus & Company, Incorporated is also acting as book manager for the proposed offering.

The offer will be made only by means of a prospectus. Copies of the preliminary prospectus relating to this offering, when available, can be obtained from: BofA Securities, NC1-004-03-43, 200 North College Street, 3 rd Floor, Charlotte, NC 28255-0001, at attention of: Prospectus Department or by e-mail to dg.prospectus—[email protected]; Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282, Attn: Prospectus Department or by email at [email protected]; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn .: Prospectus Department or by email at [email protected]

A registration statement relating to the shares sold under this offer was declared effective by the United States Securities and Exchange Commission on October 28, 2021. This press release does not constitute an offer to sell or a solicitation of an offer to purchase such securities, nor will there be a sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the laws of the securities of that state or jurisdiction.

About Sonendo, Inc.

Sonendo is a commercial-stage medical technology company focused on protecting teeth against tooth decay, the world’s most common chronic disease. Sonendo has developed the GentleWave® System, an innovative technological platform designed to treat tooth decay by cleaning and disinfecting microscopic spaces inside teeth without the need to remove tooth structure. The system uses a proprietary mechanism of action, which combines procedural fluid optimization, broad-spectrum acoustic energy, and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system during a less invasive procedure that preserves tooth structure. The clinical advantages of the GentleWave System over conventional root canal treatment methods include improved clinical outcomes, such as superior cleaning independent of root canal complexity and tooth anatomy, high healing rates, and rapid and minimal or no postoperative pain. . In addition, the GentleWave system can improve the workflow and economy of dental practices. Sonendo is also the parent company of TDO® Software, the developer of widely used endodontic practice management software solutions designed to simplify practice workflow. The TDO software integrates practice management, imaging, referral reports and CBCT imaging, and provides integrated communication with the GentleWave system.

Caution Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking statements, in particular with respect to the proposed initial public offering. Management has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While they believe these expectations, assumptions, estimates and projections are reasonable, these forward-looking statements are only predictions and involve known and unknown risks and uncertainties, which include the risk factors disclosed in the registration statement on the S-1 form regarding the project offers, many of which are beyond management’s control. These statements involve risks and uncertainties which may cause the actual results, performance or achievements of Sonendo to differ materially from the future results, performances or achievements expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date on which they are made. Readers are cautioned not to place undue reliance on forward-looking statements and, except as required by law, Sonendo assumes no obligation and does not intend to update or revise such forward-looking statements, whatsoever. either as a result of new information, future events, or otherwise.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211028006311/en/

CONTACT: Investor contact:

Gilmartin Group

Matt Bacso, CFA

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CANADA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY DENTAL HEALTH MEDICAL DEVICES

SOURCE: Sonendo, Inc.

Copyright Business Wire 2021.

PUB: 10/28/2021 10 p.m. / DISC: 10/28/2021 10:01 p.m.

http://www.businesswire.com/news/home/20211028006311/en

Copyright Business Wire 2021.


Source link

Leave A Reply

Your email address will not be published.